Literature DB >> 29437968

Induction of Interferon Kappa in Human Papillomavirus 16 Infection by Transforming Growth Factor Beta-Induced Promoter Demethylation.

Brittany L Woodby1, William K Songock1, Matthew L Scott1, Gaurav Raikhy1, Jason M Bodily2.   

Abstract

Persistent high-risk human papillomavirus (HPV) infection is the major causal factor in cervical and other anogenital cancers. Because there are currently no therapeutics capable of preventing neoplastic progression of HPV infections, understanding the mechanisms of HPV-mediated persistence, including immune evasion, is a major research priority. The multifunctional growth factor transforming growth factor beta (TGFβ) has been shown to inhibit expression of early viral transcripts from cells harboring integrated HPV genomes or cells infected with retroviruses expressing HPV oncoproteins. However, the mechanism of TGFβ-induced inhibition has not been fully defined. In this study, we have observed a previously uncharacterized ability of TGFβ to repress the differentiation-induced upregulation of late HPV16 gene expression. In addition, interferon kappa (IFN-κ), a keratinocyte-specific, constitutively expressed cytokine suppressed by differentiation, can be transcriptionally induced by TGFβ1. TGFβ-mediated IFN-κ transcription only occurs in cells containing HPV16, and this is due to TGFβ1-mediated reversal of HPV-induced methylation of the IFN-κ promoter through active DNA demethylation mediated by thymine DNA glycosylase (TDG). This novel interaction between growth factor and innate immune signaling may shed light on the mechanisms of HPV persistence and how the virus manipulates both immune and growth factor signaling to promote its life cycle.IMPORTANCE Persistent infection by high-risk HPVs is the primary risk factor for development of HPV-induced cancers. Persistence involves viral evasion of the immune response, including the IFN response. HPV is also known to suppress TGFβ signaling, which inhibits viral gene expression. Here, we show that the TGFβ and IFN pathways are interrelated in the context of HPV16 infection through the upregulation of IFN-κ by TGFβ. The ability of TGFβ to induce IFN-κ promoter demethylation and transcriptional activation provides a new explanation for why HPV has evolved mechanisms to inhibit TGFβ in infected cells.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  differentiation; innate immunity; interferon; keratinocytes; methylation; papillomaviruses; transcriptional regulation; transforming growth factor-beta

Mesh:

Substances:

Year:  2018        PMID: 29437968      PMCID: PMC5874427          DOI: 10.1128/JVI.01714-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  69 in total

1.  Differentiation of HPV-containing cells using organotypic "raft" culture or methylcellulose.

Authors:  Regina Wilson; Laimonis A Laimins
Journal:  Methods Mol Med       Date:  2005

2.  Regulation of the human papillomavirus type 16 late promoter by transcriptional elongation.

Authors:  William K Songock; Matthew L Scott; Jason M Bodily
Journal:  Virology       Date:  2017-04-24       Impact factor: 3.616

3.  Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer.

Authors:  Noriomi Matsumura; Zhiqing Huang; Seiichi Mori; Tsukasa Baba; Shingo Fujii; Ikuo Konishi; Edwin S Iversen; Andrew Berchuck; Susan K Murphy
Journal:  Genome Res       Date:  2010-12-14       Impact factor: 9.043

4.  High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression.

Authors:  Jeanette Reiser; José Hurst; Maike Voges; Peter Krauss; Peter Münch; Thomas Iftner; Frank Stubenrauch
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

5.  Lymphocytes and dendritic cells in the normal uterine cervix. An immunohistochemical study.

Authors:  W A Poppe; M Drijkoningen; P S Ide; J M Lauweryns; F A Van Assche
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1998-12       Impact factor: 2.435

6.  Expression of transforming growth factor-beta 1 and -beta 2 in human papillomavirus (HPV)-associated lesions of the uterine cervix.

Authors:  A Tervahauta; S Syrjänen; M Yliskoski; L I Gold; K Syrjänen
Journal:  Gynecol Oncol       Date:  1994-09       Impact factor: 5.482

7.  NFI-Ski interactions mediate transforming growth factor beta modulation of human papillomavirus type 16 early gene expression.

Authors:  Amy Baldwin; Lucia Pirisi; Kim E Creek
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

8.  E2 proteins of high risk human papillomaviruses down-modulate STING and IFN-κ transcription in keratinocytes.

Authors:  Nuchsupha Sunthamala; Francoise Thierry; Sebastien Teissier; Chamsai Pientong; Bunkerd Kongyingyoes; Thumwadee Tangsiriwatthana; Ussanee Sangkomkamhang; Tipaya Ekalaksananan
Journal:  PLoS One       Date:  2014-03-10       Impact factor: 3.240

Review 9.  Positive and negative regulation of TGF-beta signaling.

Authors:  K Miyazono
Journal:  J Cell Sci       Date:  2000-04       Impact factor: 5.285

10.  CREB/ATF-dependent T cell receptor-induced FoxP3 gene expression: a role for DNA methylation.

Authors:  Hyoung-Pyo Kim; Warren J Leonard
Journal:  J Exp Med       Date:  2007-06-25       Impact factor: 14.307

View more
  9 in total

1.  Suppression of Stromal Interferon Signaling by Human Papillomavirus 16.

Authors:  Gaurav Raikhy; Brittany L Woodby; Matthew L Scott; Grace Shin; Julia E Myers; Rona S Scott; Jason M Bodily
Journal:  J Virol       Date:  2019-09-12       Impact factor: 5.103

2.  Human Papillomavirus 16 E5 Inhibits Interferon Signaling and Supports Episomal Viral Maintenance.

Authors:  Matthew L Scott; Brittany L Woodby; Joseph Ulicny; Gaurav Raikhy; A Wayne Orr; William K Songock; Jason M Bodily
Journal:  J Virol       Date:  2020-01-06       Impact factor: 5.103

3.  Human papillomavirus and the landscape of secondary genetic alterations in oral cancers.

Authors:  Maura L Gillison; Keiko Akagi; David E Symer; Weihong Xiao; Bo Jiang; Robert K L Pickard; Jingfeng Li; Benjamin J Swanson; Amit D Agrawal; Mark Zucker; Birgit Stache-Crain; Anne-Katrin Emde; Heather M Geiger; Nicolas Robine; Kevin R Coombes
Journal:  Genome Res       Date:  2018-12-18       Impact factor: 9.043

Review 4.  Shared and Unique Features of Human Interferon-Beta and Interferon-Alpha Subtypes.

Authors:  Megen C Wittling; Shannon R Cahalan; Eric A Levenson; Ronald L Rabin
Journal:  Front Immunol       Date:  2021-01-19       Impact factor: 7.561

Review 5.  Role of Immunity and Vaginal Microbiome in Clearance and Persistence of Human Papillomavirus Infection.

Authors:  Lungelo Ntuli; Andile Mtshali; Gugulethu Mzobe; Lenine Jp Liebenberg; Sinaye Ngcapu
Journal:  Front Cell Infect Microbiol       Date:  2022-07-07       Impact factor: 6.073

Review 6.  Regulation of the Innate Immune Response during the Human Papillomavirus Life Cycle.

Authors:  Cary A Moody
Journal:  Viruses       Date:  2022-08-17       Impact factor: 5.818

Review 7.  Governing HPV-related carcinoma using vaccines: Bottlenecks and breakthroughs.

Authors:  Rahul Bhattacharjee; Lamha Kumar; Archna Dhasmana; Tamoghni Mitra; Abhijit Dey; Sumira Malik; Bonglee Kim; Rohit Gundamaraju
Journal:  Front Oncol       Date:  2022-09-13       Impact factor: 5.738

8.  Suppression of a Subset of Interferon-Induced Genes by Human Papillomavirus Type 16 E7 via a Cyclin Dependent Kinase 8-Dependent Mechanism.

Authors:  Sadie Rice; Seong-Man Kim; Cynthia Rodriguez; William Songock; Gaurav Raikhy; Rebecca Lopez; Lauren Henderson; Arjun Yusufji; Jason Bodily
Journal:  Viruses       Date:  2020-03-13       Impact factor: 5.048

9.  Immune outcomes of Zika virus infection in nonhuman primates.

Authors:  Blake Schouest; Marissa Fahlberg; Elizabeth A Scheef; Matthew J Ward; Kyra Headrick; Dawn M Szeltner; Robert V Blair; Margaret H Gilbert; Lara A Doyle-Meyers; Victoria W Danner; Myrna C Bonaldo; Dawn M Wesson; Antonito T Panganiban; Nicholas J Maness
Journal:  Sci Rep       Date:  2020-08-03       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.